Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease

doi:10.1016/0268-960X(91)90032-8

Blood Reviews

Volume 5, Issue 3, September 1991, Pages 155-161

https://doi.org/10.1016/0268-960X(91)90032-8 Get rights and content

Abstract

In the majority of patients with congenital and acquired von Willebrand disease (vWD), desmopressin (DDAVP) is able to increase circulating factor VIII coagulant (VIII:C) to levels sufficient to secure satisfactory hemostasis. The bleeding time (BT) is also often normalized. In this review, all cases of vWD treated with DDAVP for the prevention or control of hemorrhage and reported in the literature for whom at least basal and peak values of VIII:C were available have been analysed. When reported, the effect on the BT was also considered. It appears that, in keeping with clinical experience gained with blood products, the correction of VIII:C defect is often sufficient to secure normal hemostasis. The only significant exception is mucosal bleeding, for which the correction of BT also appears to be necessary. Several patients (mainly with type I vWD) with basal VIII:C levels of 5–10% have been successfully treated to prevent bleeding after tooth extractions and minor surgery and to control spontaneous and post-traumatic bleeding. Experience with DDAVP in major surgery is still limited, so that the compound cannot be recommended for routine use. In acquired vWD, a trial with DDAVP is advised before resorting to substitutive therapy with blood derivatives. Since side effects to DDAVP treatment are limited and no major complications have been consistently demonstrated, DDAVP can be proposed as the treatment of first choice for most patients with vWD. The recent availability of concentrated preparations of DDAVP for intranasal administration and the demonstration that the subcutaneous route is an effective and simpler alternative to the intravenous route should further facilitate its use and make home-therapy feasible.

References (75)

F Rodeghiero et al.
Epidemiological investigation of the prevalence of von Willebrand's disease
Blood
(1987)
CF Abildgaard et al.
Serial studies in von Willebrand's disease: variability versus ‘variants’
Blood
(1980)
PM Mannucci
Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders
Blood
(1988)
PM Mannucci et al.
Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor
Blood
(1985)
G Ciavarella et al.
High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (Type IC)
Blood
(1985)
HJ Weiss et al.
A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers
Blood
(1986)
L Holmberg et al.
von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma
Blood
(1986)
PM Mannucci et al.
von Willebrand disease ‘Vicenza’ with larger-than-normal (supranormal) von Willebrand factor multimers
Blood
(1988)
M Nishino et al.
New variant of von Willebrand disease with defective binding to factor VIII
Blood
(1989)
HR Gralnick et al.
DDAVP in type IIA von Willebrand's disease
Blood
(1986)

ZM Ruggeri et al.

Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes

Blood

(1982)

J Batlle et al.

The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors

Blood

(1986)

WE Fowler et al.

DDAVP for type II B von Willebrand disease

Blood

(1989)

PM Mannucci et al.

A variant of von Willebrand's disease characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers

Blood

(1983)

PM Mannucci et al.

A new variant of type II von Willebrand disease with aberrant multimeric structure of plasma but not platelet von Willebrand factor (Type IIF)

Blood

(1986)

F Rodeghiero et al.

Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A

Blood

(1989)

A Ghirardini et al.

Clinical evaluation of subcutaneously administered DDAVP

Thrombosis Research

(1988)

C Menon et al.

Beneficial effect of DDAVP on bleeding time in von Willebrand's disease

Lancet

(1978)

W Theiss et al.

DDAVP in von Willebrand's disease: repeated administration and the behaviour of the bleeding time

Thrombosis Research

(1978)

PM Mannucci et al.

DDAVP in hemophilia

Lancet

(1977)

U Budde et al.

Acquired von Willebrand's disease in the myeloproliferative syndrome

Blood

(1984)

PM Mannucci et al.

Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies

Blood

(1984)

JC Gill et al.

Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects

Blood

(1986)

F Rodeghiero et al.

von Willebrand factor abnormalities in two patients with uraemia

Lancet

(1988)

AMA Gader et al.

The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline, soprenaline and salbutamol in man

Thrombosis Research

(1973)

E Rydin et al.

Tranexamic acid and intracrasial thrombosis

Lancet

(1976)

D Davies et al.

Tranexamic acid and arterial thrombosis

Lancet

(1977)

JR O'Brien et al.

Desmopressin and myocardial infarction

Lancet

(1989)

PM Mannucci et al.

Desmopressin and thrombosis

Lancet

(1989)

HA Perkins

Correction of the hemostatic defects in von Willebrand's disease

Blood

(1967)

EE Czapek et al.

Humate- P for treatment of von Willebrand disease

Blood

(1988)

ZM Ruggeri et al.

von Willebrand factor and von Willebrand disease

Blood

(1987)

HJ Weiss et al.

Stabilization of factor VIII in plasma by von Willebrand factor

Journal of Clinical Investigation

(1977)

PM Mannucci et al.

DDAVP: a new pharmacological approach to the management of haemophilia and von Willebrand's disease

Lancet

(1977)

DW Richardson et al.

Desmopressin

Annals of Internal Medicine

(1985)

PM Mannucci

Desmopressin (DDAVP) for treatment of disorders of hemostasis

Progress in Hemostasis and Thrombosis

(1986)

IM Nilsson

von Willebrand's disease from 1926–1983

Scand J Haematol (Suppl)

(1984)

Cited by (69)

A personalized approach to the management of VWD
2019, Transfusion and Apheresis Science
Citation Excerpt :
Essentially, a responder to DDAVP should elevate the baseline VWF:RCo and FVIII:C levels with sufficient magnitude and sustained duration to ensure control of a specific hemostatic challenge. The majority of type 1 VWD (˜80%) will respond with a sufficient increase in VWF to achieve and maintain hemostasis, however, depending on the severity of type 1 VWD, a minority of patients will not respond adequately, especially if baseline levels are less than 10IU/dL [17–19]. This contrasts to patients with low VWF (baseline VWF levels of 30-50IU/dL) whereby 100% sustained responses were noted with DDAVP [20].
The goal of treating Von Willebrand Disease (VWD) is to replace deficient or dysfunctional Von Willebrand Factor (VWF) protein. However, the choice of treatment has to be considered carefully in view of patient factors and the unique properties of replacement products. Tailoring a treatment plan to an individual patient’s bleeding challenge is an intricate process. This review describes personalization of treatment selection for desmopressin (DDAVP), VWF replacement concentrates, including the newly available recombinant VWF (rVWF) and prophylaxis as a treatment approach in VWD.
Von willebrand disease: Screening, diagnosis, and management
2008, Aesthetic Surgery Journal
Von Willebrand disease (vWD), a hemorrhagic disorder mimicking a defect in platelet function, is the most commonly inherited coagulopathy, resulting in a deficiency that may prolong bleeding time and increase risk for major bleeding complications during surgery. Von Willebrand factor (vWF) serves a dual role in hemostasis: mediating the initial platelet adhesion to damaged endothelium at the site of vessel injury and stabilizing coagulation factor VIII, an important cofactor in the generation of a fibrin clot. Although quantitative or qualitative defects in vWF protein can manifest as a mild to severe bleeding disorder, many cases of vWD remain subclinical, barring major invasive stimuli, and undetected by either patient or clinician. Nevertheless, the frequency of this coagulation disorder would almost ensure that every plastic surgeon will encounter affected patients, making a thorough understanding of vWD and its management absolutely necessary. Surprisingly, there is little information concerning vWD in the plastic surgery literature. Our goal is to familiarize the plastic surgeon with vWD, including physiology, diagnostic criteria, classification, and molecular basis for multiple vWD variants, and diagnosis and management.
Neuraxial anesthesia for cesarean delivery in a parturient with type 1 von Willebrand disease and scoliosis
2007, Journal of Clinical Anesthesia
Citation Excerpt :
Desmopressin acetate is a synthetic analogue of vasopressin that increases plasma vWF and factor VIII levels. Previous work has described an increase in vWF levels of up to three to 5 times higher than baseline levels within 30 to 60 minutes after DDAVP administration [15]. Patients with type 1 vWD are likely to show a good response to DDAVP.
Recent acquisitions in acquired and congenital von Willebrand disorders
2007, Clinica Chimica Acta
Citation Excerpt :
In type 2N, relatively high levels of FVIII are observed following DDAVP, but released FVIII circulates for a shorter time period in patient plasma because the stabilizing effect of VWF is impaired. Finally, patients with type 3 VWD are usually unresponsive to DDAVP [30–33]. For those VWD patients in whom DDAVP is either ineffective or contraindicated, VWF and FVIII levels can be restored by the infusion of virus-inactivaed plasma-derived concentrates of these proteins.
von Willebrand factor is a multimeric plasma protein that mediates platelet adhesion as well as platelet aggregation at sites of vascular injury and, moreover, acts as a carrier of factor VIII. Its deficiency is associated with a bleeding tendency. The progresses in the pathophysiology, diagnosis and management of inherited von Willebrand disease and acquired von Willebrand syndrome will be discussed in this review.
The platelet function analyzer (PFA)-100
2007, Platelets
The platelet function analyzer (PFA)-100
2006, Platelets, Second Edition

View all citing articles on Scopus

View full text